Howard Rawstron

Howard has undertaken a diverse range of roles in the financial services sector spanning the disciplines of operational management, corporate relationship management, strategy and risk management.

Passionate about preventing Economic Crime his current role is to provide Oversight of Economic Crime risks with particular focus on screening and transaction monitoring.

He is an advisory board member for Cifas, the UKs largest cross-sector fraud data sharing organisation, as well as a member of the European Banking Federation Exco financial crime strategy group. He is also an active member of the Europol Financial Intelligence Public Private Partnership.

As an active LinkedIn member Howard regularly shares thoughts and insights into the world of Economic Crime Prevention and the latest developments around the globe.

Angela Ho-Chen

Angela Ho-Chen currently serves as Managing Counsel – Regulatory for RAI Services Company (Reynolds American, Inc.).

Angela’s career has spanned nearly 20 years in the medical device and tobacco regulatory arenas. She served as Division Regulatory Counsel and Regulatory Counsel at FDA’s Center for Tobacco Products (CTP) for over seven years, where she was one of the founding members of the Office of Compliance and Enforcement. Prior to her time at CTP, Angela served as a Consumer Product Safety Officer at FDA’s Center for Devices and Radiological Health. Following her time at FDA, she transitioned into the legal and regulatory departments at Altria Client Services and Juul Labs. Before joining Reynolds, Angela consulted at FDA Regulatory and Legal Services, a firm she founded following her time at Juul.

Angela has extensive cross-functional regulatory and legal leadership and project management experience. Her legal and regulatory review portfolio includes premarket and postmarket regulatory submissions strategy and execution, gap analyses, marketing and labeling reviews, inspection/audit readiness, compliance analyses, and enforcement mitigation in medical devices and tobacco. She has assisted clients with interpreting the Food, Drug, and Cosmetic Act, the Family Smoking Prevention and Tobacco Control Act, and their implementing regulations.

Angela received her BA from Emory University, her MPH in Cancer Epidemiology and Biostatistics and MPA from the University of Miami, and her JD from American University.


Paul Thomas

Paul is currently Head of Insights for EMEA and Shopper at Beam Suntory, prior to that he was Global Head of Insights for Asahi, and also headed up Insights for Africa at Diageo and looked after Insights in the UK for Ferrero.   Paul has also held pure innovation roles, and has worked across a number of agencies.

Paul’s superpowers in research are around team leadership, cultural understanding and simplification – landing big insights in the simplest way possible to drive business change.

Stanley Lewis

Stanley Lewis, MD MPH is a graduate of the University of Texas McGovern Medical School and the University of Texas School of Public Health.  He completed an Internal Medicine residency and fellowship and joined the faculty as Assistant Professor of Medicine.  Dr. Lewis has dedicated his professional career to patient care, teaching, clinical research, and drug development.  His areas of interest are infectious disease, oncology, and metabolic disorders.  He has participated as an Investigator on over 30 clinical trials and authored over 50 scientific abstracts and publications.  Dr. Lewis served as Chief Medical Officer at both public and private biotechnology companies including TaiMed Biologics where he led a small team to develop the first monoclonal antibody for treatment of multi-drug resistant HIV disease.  He later Founded and serves as CEO of A28 Therapeutics where he is developing a targeted lytic peptide for treatment of cancer.

Ed Carmines

Ed Carmines PhD brings over a three decades of experience in regulatory and compliance solutions within the tobacco and nicotine industry. He is a proven leader with the ability to merge science and business.  He has extensive experience with the Center for Tobacco Products at the FDA. He has a proven track record with Premarket Tobacco Applications, Modified Risk Tobacco Applications, Substantial Equivalence, and Exemptions Requests. He is known for his detailed knowledge of the technical aspects of all types of e-cigarettes, oral tobacco, tobacco leaf free oral products, cigars, Heat Not Burn products and cigarettes as well as the regulatory requirements for product authorization. He is known for his ability to understand complex scientific problems and to develop business relevant solutions.

During his tenure at Altria, Ed was initially responsible for the safety of cigarettes worldwide.  He played a pivotal role in designing and executing a program to test the safety of ingredients and materials used in the manufacture of cigarettes. He was intimately involved in the development of new reduced risk products including the original Heat Not Burn product, Accord. This product was the precursor to IQOS. At the end of Ed’s career at Altria, he was responsible for innovation. His team was involved in finding and evaluating new technology and products. After retiring from Altria, Ed was employed by Reynolds. His role there was shepherding product safety review of novel and oral products. He was involved in the early development of the VUSE e-cigarette.

Ed has been a consultant to the tobacco industry for over 20 years. He single handedly designed the program, executed the studies, and wrote the PMTA and MRTP applications for VLN reduced nicotine cigarettes (over 20 million pages of documents). The PMTA was authorized in 2019 and the MRTP in 2021. This is the only cigarette ever to receive market authorization. He joined Chemular in 2019 as the Chief Scientific Officer. Ed directs all aspects of the scientific studies involved in PMTA and MRTP applications. During his tenure with Chemular, Ed has directed the work on over 1000 PMTAs on all types of ENDS, smokeless tobacco, modern oral products, and novel products.

Michael Wang

Michael Wang was promoted to the role of Co-Chief Executive Officer (CEO) on August 7, 2023. Mr. Wang had previously served as our Chief Financial Officer since August 2020. Mr. Wang is an experienced CEO, COO and President for a number of companies. From September 2018 through August 2020, he was the President, COO and then Co-CEO of The Pharm/Sunday Goods (located in California and Arizona), a vertically integrated leader in the cannabis cultivation, processing, manufacturing, distribution, wholesale, and retail industry. Mr. Wang served as President and COO of Onestop Commerce from 2013 to 2015 and as CEO from 2015 to 2018. Onestop Commerce managed all aspects of omni-channel-commerce for over 100 of the world’s top lifestyle brands and retailers. From 2005 through 2012, he was the Chief Operating and Fulfillment Officer and an investor in Zazzle, a world leader in online customization and personalization service. He started his leadership career in 1992 at Honeywell. Mr. Wang received Bachelor of Science and Master of Science degrees in Aerospace Engineering in 1983 and 1985 respectively, from the Beijing University of Aeronautics & Astronautics. In 1987, he received a Master of Science degree in Systems Engineering from Oakland University located in Rochester, Michigan. In 1992, Mr. Wang received an MBA in Finance and General Management from the University of Chicago’s Booth School of Business.